Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Maraviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maraviroc SCHEMBL20451355 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL334506 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL1053748 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL2177194 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL51991 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611449 | 1.00 | CCR5 (1.00) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611504 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL30852775 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL12611605 | 0.95 | CCR5 (0.91) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| Maraviroc SCHEMBL14168620 | 0.94 | CCR5 (0.89) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2026-03-03 | — | — | US | disclosed |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | SHIONOGI & CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4066839-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | Shionogi & Co., Ltd (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021107066-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | 塩野義製薬株式会社 | 2021-06-03 | — | — | WO | disclosed |
| US-20080039428-A1 | Antiretroviral combination therapy | PANACOS PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | RPL35, RPL7, TYMP | CCR5 683/4885KCNH2 1822/4885CYP3A4 309/4885 |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | NHERF1, INO80C, IMPA1 | CCR5 55/4885KCNH2 442/4885CYP3A4 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.